Resultados de la búsqueda 71-80 of 5554 for praluent side afects

  1. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    We also want to learn about the side effects of this combination. All study subjects will receive acalabrutinib, durvalumab, and venetoclax. Acalabrutinib ...

  2. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    We also want to learn about the side effects of this combination. All study subjects will receive acalabrutinib, durvalumab, and venetoclax. Acalabrutinib ...

  3. Ensayos clínicos - Centro Pediátrico de Mayo Clinic

    A standard treatment is considered not well tolerated if the patient experiences severe side effects without providing an acceptable level of clinical benefit.

  4. Efectos secundarios del Neurontin: ¿cómo los manejo? - Mayo Clinic

    Neurontin side effects - How do I manage them. Tu donación es muy poderosa... ¿quieres hacerla hoy mismo? Para donar. ¿Te gustaría hacer una donación ...

  5. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    The purpose of this study is to correlate gut microbiome with specific cancer diagnoses and the clinical response (effectiveness), and adverse effects of cancer ...

  6. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    We also want to learn about the side effects of this combination. All study subjects will receive acalabrutinib, durvalumab, and venetoclax. Acalabrutinib ...

  7. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    We also want to learn about the side effects of this combination. All study subjects will receive acalabrutinib, durvalumab, and venetoclax. Acalabrutinib ...

  8. Nefrología e hipertensión - Ensayos clínicos - Mayo Clinic

    A standard treatment is considered not well tolerated if the patient experiences severe side effects without providing an acceptable level of clinical benefit.

  9. Medicina pulmonar - Ensayos clínicos - Mayo Clinic

    A standard treatment is considered not well tolerated if the patient experiences severe side effects without providing an acceptable level of clinical benefit.

  10. Untitled

    Page 1.